Sutro Biopharma, Inc.
Hedge Funds Holdings
Last updated:
Sutro Biopharma, Inc.‘s stocks are currently a part of 112 hedge funds’ portfolios, which represents 90.38% of the total amount of its stocks outstanding. This makes up a total of 41.72M shares of Sutro Biopharma, Inc.. Compared to the previous quarter, the number grew by 4.67% or 1.85M shares more. As for the holding position changes, 34.82% (39) of current hedge fund investors increased the number of shares held, 31.25% (35) of current holders sold a part of the shares held, and 24.11% (27) closed the holdings completely. 23 hedge funds are new holders of Sutro Biopharma, Inc. stock in Q1 2022, it is 20.54% of total holders.
Hedge funds holding Sutro Biopharma (Q3 2018 – Q1 2022)
| Q3 2018 | 32 |
|---|---|
| Q4 2018 | 43 |
| Q1 2019 | 49 |
| Q2 2019 | 58 |
| Q3 2019 | 58 |
| Q4 2019 | 63 |
| Q1 2020 | 59 |
| Q2 2020 | 77 |
| Q3 2020 | 85 |
| Q4 2020 | 133 |
| Q1 2021 | 137 |
| Q2 2021 | 122 |
| Q3 2021 | 119 |
| Q4 2021 | 116 |
| Q1 2022 | 112 |
Hedge funds changes in Sutro Biopharma positions (Q3 2018 – Q1 2022)
| Q3 2018 | 32 | 0 | 0 | 0 | 0 |
|---|---|---|---|---|---|
| Q4 2018 | 23 | 8 | 7 | 11 | -6 |
| Q1 2019 | 8 | 17 | 10 | 3 | 11 |
| Q2 2019 | 12 | 20 | 15 | 3 | 8 |
| Q3 2019 | 5 | 24 | 14 | 5 | 10 |
| Q4 2019 | 11 | 25 | 9 | 6 | 12 |
| Q1 2020 | 2 | 28 | 15 | 5 | 9 |
| Q2 2020 | 22 | 34 | 11 | 3 | 7 |
| Q3 2020 | 18 | 39 | 16 | 9 | 3 |
| Q4 2020 | 61 | 45 | 17 | 13 | -3 |
| Q1 2021 | 24 | 62 | 33 | 20 | -2 |
| Q2 2021 | 12 | 49 | 43 | 27 | -9 |
| Q3 2021 | 10 | 45 | 37 | 13 | 14 |
| Q4 2021 | 14 | 44 | 39 | 17 | 2 |
| Q1 2022 | 23 | 39 | 35 | 27 | -12 |
Hedge funds changes in Sutro Biopharma stock options (Q3 2018 – Q1 2022)
| Q3 2018 | 0 | 0 |
|---|---|---|
| Q4 2018 | 0 | 0 |
| Q1 2019 | 0 | 0 |
| Q2 2019 | 0 | 0 |
| Q3 2019 | 0 | 0 |
| Q4 2019 | 0 | 0 |
| Q1 2020 | 0 | 0 |
| Q2 2020 | 0 | 0 |
| Q3 2020 | 0 | 0 |
| Q4 2020 | 1,495,000 | 763,000 |
| Q1 2021 | 6,063,000 | 1,353,000 |
| Q2 2021 | 258,000 | 213,000 |
| Q3 2021 | 11,000 | 1,000 |
| Q4 2021 | 24,000 | 1,987,000 |
| Q1 2022 | 0 | 0 |